Question
Asked 7 January 2016

I need to score the Physicial Activity Scale For The Elderly (PASE), could anyone help me? And what is the maximum score?

Could you help?

Popular answers (1)

Martin Hofmeister
Consumer Centre of the German Federal State of Bavaria, Germany, Munich
Dear Lizzy,
“The Physical Activity Scale for the Elderly (PASE) assesses the types of activities typically chosen by older adults (walking, recreational activities, exercise, housework, yard work, and caring for others. It uses frequency, duration, and intensity level of activity over the previous week to assign a score, ranging from 0 to 793, with higher scores indicating greater physical activity.
Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153-62. https://www.researchgate.net/publication/14762341_The_Physical_Activity_Scale_for_the_Elderly_PASE_Development_and_evaluation
Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol. 1999;52(7):643-51. http://www.jclinepi.com/article/S0895-4356%2899%2900049-9/abstract
Logan SL, Gottlieb BH, Maitland SB, Meegan D, Spriet LL. The Physical Activity Scale for the Elderly (PASE) questionnaire; does it predict physical health? Int J Environ Res Public Health. 2013 Aug 30;10(9):3967-86. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799529/pdf/ijerph-10-03967.pdf 
Best wishes from Germany
Martin
5 Recommendations

All Answers (2)

Martin Hofmeister
Consumer Centre of the German Federal State of Bavaria, Germany, Munich
Dear Lizzy,
“The Physical Activity Scale for the Elderly (PASE) assesses the types of activities typically chosen by older adults (walking, recreational activities, exercise, housework, yard work, and caring for others. It uses frequency, duration, and intensity level of activity over the previous week to assign a score, ranging from 0 to 793, with higher scores indicating greater physical activity.
Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153-62. https://www.researchgate.net/publication/14762341_The_Physical_Activity_Scale_for_the_Elderly_PASE_Development_and_evaluation
Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol. 1999;52(7):643-51. http://www.jclinepi.com/article/S0895-4356%2899%2900049-9/abstract
Logan SL, Gottlieb BH, Maitland SB, Meegan D, Spriet LL. The Physical Activity Scale for the Elderly (PASE) questionnaire; does it predict physical health? Int J Environ Res Public Health. 2013 Aug 30;10(9):3967-86. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799529/pdf/ijerph-10-03967.pdf 
Best wishes from Germany
Martin
5 Recommendations
Evaristo V. Fernandes
University of Aveiro
The score 100 (one hundred) will be the standard of Man’s normal biophysics. Down such a scale you would meet the developments of variables estimated dimensions of the individual de-velopments in analysis. Distribute these dimensions from hundred (100) to 0 (zero), and then, make analysis and work-up the correlations between all behavioral dimensions of the person. The neuropsychiatric rehabilitation processes of the elderly and biophysical would focus on the most fragile dimensions of the elderly.

Similar questions and discussions

Effect Size Measures for Wilcoxon Signed-Rank Test in Likert Scale Data Analysis?
Question
3 answers
  • Adam R.S. BartonAdam R.S. Barton
Hello ResearchGate community,
I'm currently analyzing a dataset derived from a survey of ~200 paired responses across two time points. The survey is of teachers and students, using 60 Likert-like items to assess beliefs about education. After factor analysis, I derived three core factors.
I'm now trying to assess the relative magnitude of change in factor scores over two time points. I say relative magnitude because, for all factors, the scores decreased. So I need to see 1) whether changes were significant and 2) the size of those changes.
Preliminary tests, including Shapiro-Wilk, Q-Q plots, and outlier detection, indicated non-normality, guiding me to utilize a Wilcoxon signed-rank test.
However, I'm at a crossroads regarding the appropriate effect size measure. Traditional non-parametric effect size measures, like rank biserial correlation, seem to fall short for my purpose, as they primarily address the probability of difference -- rather than the magnitude of change I'm interested in capturing. I've established that two factors saw a statistically significant change using Wilcoxon signed rank. But I need to understand how big these deceases were and hopefully compare the two.
I'm contemplating justifying the use of Cohen's d or exploring median-based measures for a more accurate reflection of the change magnitude. But I'm struggling to find relevant info online. I've seen references to things like Hodges Lehmann, using simple median change, etc. But nothing solid.
Does anyone have insights or references on how to effectively apply a median measure in this context or justify using Cohen's d with the Wilcoxon signed-rank test for ordinal Likert data?
I appreciate any guidance or shared experiences on this matter.
Can we perform a MANCOVA for paired data?
Question
4 answers
  • Youssef SolimanYoussef Soliman
I have data for a cross-over randomized controlled trial. I wonder if I can use MANCOVA to compare my outcomes (they are continuous) while having paired data. If I can't, what would be an appropriate test here? I have some covariates that I want to account for. I already did some Wilcoxon tests, but it didn't account for covariates.
The design of the study is as follows:
There are two groups: Group is given treatment (a drug) and then control (Sequence AP). Another group is given control then treatment (the same drug) (PA sequence). Between the treatment and control, there is a washout period.
I have four DVs that are continuous. Each variable is measured two times. For example, the AP sequence had the variables measured one time after the intervention (t0) and another time after the place (t1). Same thing for the PA sequence. They had the placebo, then had the variables measured (t0), then a washout period, then the intervention, and then the DVs were measured again (t1). I have covariates that are measured at baseline (before the study starts). So think of my data as a dataframe with the following columns:
1- Sequence (AP vs PA)
2- t0 (DV1)
3- t1 (DV1)
4- Covariate 1
5- Covariate 2
and so on
I would like to:
1- Compare between t0 and t1 for each sequence while controlling for covariates. I started with Wilcoxon test to compare t0 and t1 considering that this is paired data and some of the DVs are not normally distributed. However, I know that Wilcoxon doesn't account for my covariates. I thought about using MANCOVA (but am not sure if it is the right one because some of my DVs are not normally distributed and my data is paired data). Ignoring the normality thing, can we use MANCOVA for this scenario? In case of Mancova, I will have to convert my wide data to long data (i.e., instead of having each DV presented as column t0 once and t1 once, I will put them on top of each other). My DVs would be my four continuous DVs, then we have an independent categorical variable (drug vs placebo) and continuous covariates. I can do that for each sequence separately, then combine them.
Btw, Wilcoxon didn't find any significant difference.
2- If MANCOVA is not valid, what would be a simple but robust solution?
The correlation method below would work? I assume if the difference between t0 and t1 is not correlated with my covariates, then it is unlikely that they might be confounding variables.
Update: I am thinking of using correlation between the difference in my DVs (t1-t0) with my covariates to create a correlation matrix. If they are not significant, then it is safe to say that these covariates are not confounding my results. Does that make sense?
Any advice?
How to cite clinical trials using Endnote?
Question
2 answers
  • Rizwan QaisarRizwan Qaisar
I downloaded and saved the clinicaltrials filter for endnote. I downloaded the relevant file as plain text from clinicaltrials.gov, and imported it to Endnote. But I cannot find it in my Endnote library. No error message appears either.
I basically followed this tutorial step by step,
Two observations,
1. My page from the Clinicaltrials website (screenshot below) seems different than the one shown in the video at 0:32.
2. The downloaded plain text file in the tutorial (shown at 2:16) seems to have way more details than mine, which only shows NCT number.
But the problem is, when I try to download a relevant file for a clinical trial (no matter ongoing or completed trial), I see this message,
'''Data Fields
Currently only NCTId field is available to download for Text format''.
I suspect this is the problem, but any idea how to go around it?
thanks
- Qaisar

Recommendations

Article
Assessment of Physical Activity in obese youth after an intervention program: a comparison between questionnaire and accelerometry measurement Objective: The aim of the present study was to compare changes in PA using a self-reported physical activity questionnaire vs. accelerometer output. Methods: Twenty-eight obese youth were measured for physic...
Article
Introduction L’inactivite physique a un impact important sur l’etat de sante des patients atteints de mucoviscidose. Le but de cette etude est d’evaluer, chez des patients atteints de mucoviscidose, l’interet de questionnaire comme le score d’activite physique de Dijon et l’autoquestionnaire de Baecke deja valides chez des sujets sains comme outils...
'If we want to develop AI that helps people, we need all the brainpower we can get.'
Sponsored Content
To build the best artificial intelligence, we don't just need computing power and new technology, argues Pim Haselager. If we want to develop AI that helps people, we need all the brainpower we can get. This includes people from all walks of life where AI will play a role. Only then can we properly understand the implications of this new technology.
Haselager is affiliated with Radboud University as a professor of Societal Implications of AI and directs a research group with the same title. In his research, he focuses on the responsible, interdisciplinary development and application of artificial intelligence and cognitive neuroscience. Haselager: ‘A responsible use of AI and cognitive neuroscience requires constructive ethics that must be in place early on. It is precisely in the research and development phase of technology that social expectations and concerns should be able to play an important role.’
‘Topics such as human-robot interaction, decision support machines, chatbots, and direct communication between brain and computer require a social discussion on the development and use of technology,’ says the researcher. ‘We have a long history of prejudice as a human race, a bias that we base our decisions on. If we're not careful, that bias will be adopted by self-learning AI systems.’ However, it can be difficult to prevent this from happening - especially on your own, and especially if you may also have certain (unconscious) biases yourself. ‘To think about this wisely and talk about it in a balanced way, diversity is a prerequisite,’ Haselager points out.
Got a technical question?
Get high-quality answers from experts.